Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Daclatasvir/ sofosbuvir bulk supplier for pharma manufacturers

Daclatasvir/ Sofosbuvir Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Daclatasvir 60 mg + Sofosbuvir 400 mg

Reference Brands: Hepcinat Plus (India), Myhep Dvir (India)

Category: Hepatitis

Daclatasvir and Sofosbuvir tablets are a potent oral antiviral combination for treating chronic Hepatitis C infection. This fixed-dose therapy targets multiple HCV genotypes by inhibiting viral replication enzymes. Manufactured under EU-GMP and USFDA standards, it is widely used in B2B supply, hospital tenders, and global markets with full regulatory support for quick registration.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Daclatasvir and Sofosbuvir Tablets are an oral, fixed-dose combination used to treat chronic Hepatitis C infection across multiple genotypes. Daclatasvir is an NS5A inhibitor, and Sofosbuvir is an NS5B polymerase inhibitor; together, they provide a highly effective, well-tolerated antiviral regimen. Available as 60 mg Daclatasvir and 400 mg Sofosbuvir tablets, manufactured under EU-GMP and USFDA standards. Ideal for B2B licensing, hospital tenders, and global distribution with full CTD dossiers for fast registration in regulated markets.

Daclatasvir/ Sofosbuvir — third party manufacturing & bulk supply

Daclatasvir/ Sofosbuvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Daclatasvir/ Sofosbuvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Daclatasvir/ Sofosbuvir →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Daclatasvir + Sofosbuvir is used for the treatment of chronic hepatitis C virus (HCV) infection, mainly genotypes 1, 3, and others as per clinical requirement. It helps reduce viral load and supports complete viral clearance when taken as a combination therapy.

It is made from the active ingredients daclatasvir, an NS5A inhibitor, and sofosbuvir, an NS5B polymerase inhibitor. Together they block viral replication and prevent the hepatitis C virus from multiplying.

Common trade names include Daklinza (daclatasvir) and Sovaldi (sofosbuvir) when sold separately. Combined generic formulations are available in India and other regions under several brand names.

Daklinza (daclatasvir) is made by Bristol-Myers Squibb, and Sovaldi (sofosbuvir) is made by Gilead Sciences. Combination generics are produced by multiple licensed manufacturers in India and other countries.

The generic name is daclatasvir + sofosbuvir.

Brand names include Daklinza (daclatasvir), Sovaldi (sofosbuvir), and various combined generic brands depending on the region.

It is manufactured by Bristol-Myers Squibb and Gilead Sciences, along with licensed generic manufacturers in India and several other global regions.

Related Products

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir

Strength:
Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet)

Form: Tablet

Reference Brands: Viekira Pak® (US); Viekirax® + Exviera® (EU)

View Details
Ribavirin

Strength:
Tablet:200 mg, 400 mg, 600mg; Capsule:200 mg; Solution:40 mg/mL

Form: Tablets, Capsules and Oral Solution

Reference Brands: Rebetol®, Copegus®, Virazole®(EU & US)

View Details
Adefovir Dipivoxil

Strength:
10 mg

Form: Oral tablets

Reference Brands: Hepsera® (EU & US)

View Details
Tenofovir Alafenamide (Taf)

Strength:
25 mg TAF per tablet

Form: Tablet

Reference Brands: Vemlidy (EU & US), Genvoya (India)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.